Related Experiment Video
Updated: Jul 1, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Laser assisted pulmonary metastasectomy promises a low local recurrence rate
Ahmad Shalabi1, Ahmed Ehab2,3, Sundus F Shalabi4
1Thoracic and Vascular Surgery Department, SLK Lung Medical Center Löwenstein, Löwenstein, Germany. ahmadfshalabi@gmail.com.
Abstract:
Pulmonary metastasectomy (PM) is consensually performed in a parenchyma-sparing manner to preserve functionally healthy lung tissue. However, this may increase the risk of local recurrence at the surgical margin. Laser assisted pulmonary metastasectomy (LPM) is a relatively recent innovation that is especially useful to resect multiple metastatic pulmonary nodules. In this study we investigated the rate of local recurrence after LPM and evaluated the influence of various clinical and pathological factors on local recurrence. Retrospectively, a total of 280 metastatic nodules with different histopathological entities were studied LPM from 2010 till 2018. All nodules were resected via diode-pumped neodymium: yttrium-aluminum-garnet (Nd:YAG) 1,318 nm laser maintaining a safety margin of 5 mm. Patients included were observed on average for 44 ± 17 months postoperatively. Local recurrence at the surgical margin following LPM was found in 9 nodules out of 280 nodules (3.21%). Local recurrence at the surgical margin occurred after 20 ± 8.5 months post operation. Incomplete resection (p = < 0.01) and size of the nodule (p = < 0.01) were associated with significantly increased risk of local recurrence at the surgical margin. Histology of the primary disease showed no impact on local recurrence. Three and five-year survival rates were 84% and 49% respectively. Following LPM, the rate of local recurrence is low. This is influenced by the size of the metastatic nodules and completeness of the resection. Obtaining a safety margin of 5 mm seems to be sufficient, larger nodules require larger safety margins.
Insights
Laser assisted pulmonary metastasectomy (LPM) offers a low local recurrence rate of 3.21%. Key factors influencing recurrence include nodule size and complete resection, with a 5mm margin generally sufficient for effective treatment.
Area of Science:
- Thoracic Surgery
- Surgical Oncology
- Minimally Invasive Procedures
Background:
- Pulmonary metastasectomy (PM) traditionally aims for parenchyma-sparing resections.
- Parenchyma-sparing techniques may increase the risk of local recurrence at surgical margins.
- Laser assisted pulmonary metastasectomy (LPM) is an emerging technique for resecting multiple pulmonary nodules.
Purpose of the Study:
- To investigate the local recurrence rate following LPM.
- To evaluate the impact of clinical and pathological factors on local recurrence after LPM.
- To assess the efficacy of a 5mm safety margin in LPM.
Main Methods:
- Retrospective analysis of 280 metastatic pulmonary nodules resected using Nd:YAG laser (1,318 nm).
- All resections maintained a 5mm safety margin.
- Patient follow-up averaged 44 ± 17 months postoperatively.
Main Results:
- A local recurrence rate of 3.21% (9 out of 280 nodules) was observed.
- Local recurrence occurred at a mean of 20 ± 8.5 months post-operation.
- Incomplete resection and larger nodule size were significantly associated with increased local recurrence risk (p < 0.01).
- Histology of the primary disease did not impact local recurrence.
- Three- and five-year survival rates were 84% and 49%, respectively.
Conclusions:
- LPM demonstrates a low rate of local recurrence.
- Nodule size and completeness of resection are critical factors influencing local recurrence.
- A 5mm safety margin appears adequate, though larger nodules may necessitate wider margins.
More Related Videos
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022